104 related articles for article (PubMed ID: 38741426)
1. Expression of p16 protein in breast cancer.
Samman A; Hanbazazh M; Samargandy S; Al-Maghrabi J
Pol J Pathol; 2024; 75(1):19-24. PubMed ID: 38741426
[TBL] [Abstract][Full Text] [Related]
2. Expression of retinoblastoma protein in breast cancer metastases to sentinel nodes: evaluation of its role as a marker for the presence of metastases in non-sentinel axillary nodes, and comparison to p16INK4a.
Grupka NL; Bloom C; Singh M
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):63-70. PubMed ID: 16540733
[TBL] [Abstract][Full Text] [Related]
3. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy.
Han S; Ahn SH; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Breast Cancer Res Treat; 2001 Dec; 70(3):205-12. PubMed ID: 11804184
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
5. [Methylation and expression of gene p16INK4a and RB in breast carcinoma].
Zhao YF; Shen SP; Jiang JY; Geng H; Guo JG; Xie LP
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):377-81. PubMed ID: 21055153
[TBL] [Abstract][Full Text] [Related]
6. p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma.
Goyal A; Sahu RK; Kumar M; Sharma S; Qayyum S; Kaur N; Singh UR; Mehrotra R; Hedau S
J Cancer Res Ther; 2019; 15(5):1147-1154. PubMed ID: 31603125
[TBL] [Abstract][Full Text] [Related]
7. p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis.
Singh M; Parnes MB; Spoelstra N; Bleile MJ; Robinson WA
Hum Pathol; 2004 Dec; 35(12):1524-30. PubMed ID: 15619212
[TBL] [Abstract][Full Text] [Related]
8. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
Li Y; Qin J; Wu J; Dai X; Xu J
Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721
[TBL] [Abstract][Full Text] [Related]
9. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman.
Setyawati Y; Rahmawati Y; Widodo I; Ghozali A; Purnomosari D
Asian Pac J Cancer Prev; 2018 May; 19(5):1263-1268. PubMed ID: 29801411
[TBL] [Abstract][Full Text] [Related]
10. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of p16 Protein Expression in Breast Cancer.
Salih MM; Higgo AA; Eed EM
In Vivo; 2022; 36(1):336-340. PubMed ID: 34972731
[TBL] [Abstract][Full Text] [Related]
12. Correlations of breast cancer FHIT gene with the incidence and prognosis of breast cancer.
Fu Y; Shan X; Song W; Xu K; Jiao C; Zhang Q
J BUON; 2019; 24(1):40-47. PubMed ID: 30941950
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
14. Expression of androgen receptor and its phosphorylated forms in breast cancer progression.
Ren Q; Zhang L; Ruoff R; Ha S; Wang J; Jain S; Reuter V; Gerald W; Giri DD; Melamed J; Garabedian MJ; Lee P; Logan SK
Cancer; 2013 Jul; 119(14):2532-40. PubMed ID: 23605249
[TBL] [Abstract][Full Text] [Related]
15. [Aberrant expression and correlative analysis of P16 in breast cancers].
Cui SP; Wang HL; Peng W; Liu HJ; Hou L; Zhang B
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):755-9. PubMed ID: 23073587
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
17. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters.
Dublin EA; Patel NK; Gillett CE; Smith P; Peters G; Barnes DM
Int J Cancer; 1998 Feb; 79(1):71-5. PubMed ID: 9495362
[TBL] [Abstract][Full Text] [Related]
18. Research on expression and importance of p53, p16 and VEGF-C in cervical cancer.
Cai S; Han K
J Gynecol Obstet Biol Reprod (Paris); 2015 Sep; 44(7):639-45. PubMed ID: 25443468
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.
Reed W; Sandstad B; Holm R; Nesland JM
Int J Surg Pathol; 2003 Apr; 11(2):65-74. PubMed ID: 12754622
[TBL] [Abstract][Full Text] [Related]
20. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
